{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:38:48Z","timestamp":1790617128751,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T00:00:00Z","timestamp":1236729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s00259-009-1103-3","type":"journal-article","created":{"date-parts":[[2009,3,10]],"date-time":"2009-03-10T22:16:47Z","timestamp":1236723407000},"page":"1113-1120","source":"Crossref","is-referenced-by-count":62,"title":["Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins"],"prefix":"10.1007","volume":"36","author":[{"given":"Ferdinando","family":"Squitieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Orobello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantaleo","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Giovacchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Frati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ciarmiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,3,11]]},"reference":[{"key":"1103_CR1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington\u2019s disease. J Neuropathol Exp Neurol 1985;44:559\u201377. doi: 10.1097\/00005072-198511000-00003 .","journal-title":"J Neuropathol Exp Neurol"},{"key":"1103_CR2","first-page":"215","volume":"47","author":"A Ciarmiello","year":"2006","unstructured":"Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington\u2019s disease. J Nucl Med 2006;47:215\u201322.","journal-title":"J Nucl Med"},{"key":"1103_CR3","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/brain\/awn025","volume":"131","author":"HD Rosas","year":"2008","unstructured":"Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, et al. Cerebral cortex and the clinical expression of Huntington\u2019s disease: complexity and heterogeneity. Brain 2008;131:1057\u201368. doi: 10.1093\/brain\/awn025 .","journal-title":"Brain"},{"key":"1103_CR4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/321168a0","volume":"321","author":"MF Beal","year":"1986","unstructured":"Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington\u2019s disease by quinolinic acid. Nature 1986;321:168\u201371. doi: 10.1038\/321168a0 .","journal-title":"Nature"},{"key":"1103_CR5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"118","author":"LR Gauthier","year":"2004","unstructured":"Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordeli\u00e8res FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004;118:127\u201338. doi: 10.1016\/j.cell.2004.06.018 .","journal-title":"Cell"},{"key":"1103_CR6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ajmg.b.30501","volume":"144B","author":"A Ciammola","year":"2007","unstructured":"Ciammola A, Sassone J, Cannella M, Calza S, Poletti B, Frati L, et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington\u2019s disease patients. Am J Med Genet B Neuropsychiatr Genet 2007;144B:574\u20137. doi: 10.1002\/ajmg.b.30501 .","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"1103_CR7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","volume":"293","author":"C Zuccato","year":"2001","unstructured":"Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science 2001;293:493\u20138. doi: 10.1126\/science.1059581 .","journal-title":"Science"},{"key":"1103_CR8","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1176\/appi.ajp.159.7.1227","volume":"159","author":"RT Schaub","year":"2002","unstructured":"Schaub RT, Anders D, Golz G, G\u00f6hringer K, Hellweg R. Serum nerve growth factor concentration and its role in the preclinical stage of dementia. Am J Psychiatry 2002;159:1227\u20139. doi: 10.1176\/appi.ajp.159.7.1227 .","journal-title":"Am J Psychiatry"},{"key":"1103_CR9","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1172\/JCI27341","volume":"116","author":"I Tesseur","year":"2006","unstructured":"Tesseur I, Zou K, Esposito L, Bard F, Berber E, Can JV, et al. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer\u2019s pathology. J Clin Invest 2006;116:3060\u20139. doi: 10.1172\/JCI27341 .","journal-title":"J Clin Invest"},{"key":"1103_CR10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0306-4522(96)00336-3","volume":"75","author":"E P\u00e9rez-Navarro","year":"1996","unstructured":"P\u00e9rez-Navarro E, Arenas E, Reiriz J, Calvo N, Alberch J. Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage. Neuroscience 1996;75:345\u201352. doi: 10.1016\/0306-4522(96)00336-3 .","journal-title":"Neuroscience"},{"key":"1103_CR11","doi-asserted-by":"crossref","first-page":"9594","DOI":"10.1523\/JNEUROSCI.18-23-09594.1998","volume":"18","author":"V Bruno","year":"1998","unstructured":"Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, Nicoletti F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci 1998;18:9594\u2013600.","journal-title":"J Neurosci"},{"key":"1103_CR12","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1089\/ars.2006.8.2061","volume":"8","author":"SE Browne","year":"2006","unstructured":"Browne SE, Beal MF. Oxidative damage in Huntington\u2019s disease pathogenesis. Antioxid Redox Signal 2006;8:2061\u201373. doi: 10.1089\/ars.2006.8.2061 .","journal-title":"Antioxid Redox Signal"},{"key":"1103_CR13","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/hmg\/ddl013","volume":"15","author":"A Hodges","year":"2006","unstructured":"Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, et al. Regional and cellular gene expression changes in human Huntington\u2019s disease brain. Hum Mol Genet 2006;15:965\u201377. doi: 10.1093\/hmg\/ddl013 .","journal-title":"Hum Mol Genet"},{"key":"1103_CR14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.20684","volume":"59","author":"A Feigin","year":"2006","unstructured":"Feigin A, Ghilardi MF, Huang C, Ma Y, Carbon M, Guttman M, et al. Preclinical Huntington\u2019s disease: compensatory brain responses during learning. Ann Neurol 2006;59:53\u20139. doi: 10.1002\/ana.20684 .","journal-title":"Ann Neurol"},{"key":"1103_CR15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1468-1331.2006.01264.x","volume":"13","author":"F Squitieri","year":"2006","unstructured":"Squitieri F, Ciarmiello A, Di Donato S, Frati L. The search for cerebral biomarkers of Huntington\u2019s disease: a review of genetic models of age at onset prediction. Eur J Neurol 2006;13:408\u201315. doi: 10.1111\/j.1468-1331.2006.01264.x .","journal-title":"Eur J Neurol"},{"key":"1103_CR16","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ng1542","volume":"37","author":"F Giorgini","year":"2005","unstructured":"Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 2005;37:526\u201331. doi: 10.1038\/ng1542 .","journal-title":"Nat Genet"},{"key":"1103_CR17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1034\/j.1399-0004.2000.580108.x","volume":"58","author":"F Squitieri","year":"2000","unstructured":"Squitieri F, Berardelli A, Nargi E, Castellotti B, Mariotti C, Cannella M, et al. Atypical movement disorders in the early stages of Huntington\u2019s disease: clinical and genetic analysis. Clin Genet 2000;58:50\u20136. doi: 10.1034\/j.1399-0004.2000.580108.x .","journal-title":"Clin Genet"},{"key":"1103_CR18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.expneurol.2004.02.003","volume":"187","author":"A Bergerot","year":"2004","unstructured":"Bergerot A, Shortland PJ, Anand P, Hunt SP, Carlstedt T. Co-treatment with riluzole and GDNF is necessary for functional recovery after ventral root avulsion injury. Exp Neurol 2004;187:359\u201366. doi: 10.1016\/j.expneurol.2004.02.003 .","journal-title":"Exp Neurol"},{"key":"1103_CR19","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1096\/fj.02-0143fje","volume":"16","author":"R Katoh-Semba","year":"2002","unstructured":"Katoh-Semba R, Asano T, Ueda H, Morishita R, Takeuchi IK, Inaguma Y, et al. Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J 2002;16:1328\u201330.","journal-title":"FASEB J"},{"key":"1103_CR20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00259-007-0615-y","volume":"35","author":"F Squitieri","year":"2008","unstructured":"Squitieri F, Ciammola A, Colonnese C, Ciarmiello A. Neuroprotective effects of riluzole in Huntington\u2019s disease. Eur J Nucl Med Mol Imaging 2008;35:221\u20132. doi: 10.1007\/s00259-007-0615-y .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1103_CR21","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/brain\/awg077","volume":"126","author":"F Squitieri","year":"2003","unstructured":"Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, et al. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 2003;126:946\u201355. doi: 10.1093\/brain\/awg077 .","journal-title":"Brain"},{"key":"1103_CR22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group. The Unified Huntington\u2019s Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136\u201342. doi: 10.1002\/mds.870110204 .","journal-title":"Mov Disord"},{"key":"1103_CR23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/mrm.1910370113","volume":"37","author":"B Alfano","year":"1997","unstructured":"Alfano B, Brunetti A, Covelli EM, Quarantelli M, Panico MR, Ciarmiello A, et al. Unsupervised, automated segmentation of the normal brain using a multispectral relaxometric magnetic resonance approach. Magn Reson Med 1997;37:84\u201393. doi: 10.1002\/mrm.1910370113 .","journal-title":"Magn Reson Med"},{"key":"1103_CR24","first-page":"192","volume":"45","author":"M Quarantelli","year":"2004","unstructured":"Quarantelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L, et al. Integrated software for the analysis of brain PET\/SPECT studies with partial-volume-effect correction. J Nucl Med 2004;45:192\u2013201.","journal-title":"J Nucl Med"},{"key":"1103_CR25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/jcbfm.1992.81","volume":"12","author":"HW Muller-Gartner","year":"1992","unstructured":"Muller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992;12:571\u201383.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1103_CR26","first-page":"904","volume":"39","author":"OG Rousset","year":"1998","unstructured":"Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med 1998;39:904\u201311.","journal-title":"J Nucl Med"},{"key":"1103_CR27","unstructured":"Research Imaging Center, University of Texas Health Science Center at San Antonio. Talairach Daemon Client download. http:\/\/www.talairach.org\/client.html . Accessed 26 Feb 2009."},{"key":"1103_CR28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","volume":"62","author":"GB Landwehrmeyer","year":"2007","unstructured":"Landwehrmeyer GB, Dubois B, de Y\u00e9benes JG, Kremer B, Gaus W, Kraus PH, et al. Riluzole in Huntington\u2019s disease: A 3-year, randomized controlled study. Ann Neurol 2007;62:262\u201372. doi: 10.1002\/ana.21181 .","journal-title":"Ann Neurol"},{"key":"1103_CR29","doi-asserted-by":"crossref","first-page":"7351","DOI":"10.1523\/JNEUROSCI.18-18-07351.1998","volume":"18","author":"KM Giehl","year":"1998","unstructured":"Giehl KM, Sch\u00fctte A, Mestres P, Yan Q. The survival-promoting effect of glial cell line-derived neurotrophic factor on axotomized corticospinal neurons in vivo is mediated by an endogenous brain-derived neurotrophic factor mechanism. J Neurosci 1998;18:7351\u201360.","journal-title":"J Neurosci"},{"key":"1103_CR30","doi-asserted-by":"crossref","first-page":"9822","DOI":"10.1523\/JNEUROSCI.18-23-09822.1998","volume":"18","author":"K Krieglstein","year":"1998","unstructured":"Krieglstein K, Henheik P, Farkas L, Jaszai J, Galter D, Krohn K, et al. Glial cell line-derived neurotrophic factor requires transforming growth factor-beta for exerting its full neurotrophic potential on peripheral and CNS neurons. J Neurosci 1998;18:9822\u201334.","journal-title":"J Neurosci"},{"key":"1103_CR31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pscychresns.2007.04.001","volume":"162","author":"S Paradiso","year":"2008","unstructured":"Paradiso S, Turner BM, Paulsen JS, Jorge R, Ponto LL, Robinson RG. Neural bases of dysphoria in early Huntington\u2019s disease. Psychiatry Res 2008;162:73\u201387. doi: 10.1016\/j.pscychresns.2007.04.001 .","journal-title":"Psychiatry Res"},{"key":"1103_CR32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1440-1819.2008.01814.x","volume":"62","author":"SM Lehto","year":"2008","unstructured":"Lehto SM, Kuikka J, Tolmunen T, Valkonen-Korhonen M, Joensuu M, Saarinen PI, et al. Temporal cortex dopamine D2\/3 receptor binding in major depression. Psychiatry Clin Neurosci 2008;62:345\u20138. doi: 10.1111\/j.1440-1819.2008.01814.x .","journal-title":"Psychiatry Clin Neurosci"},{"key":"1103_CR33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10072-008-0969-3","volume":"29","author":"F Squitieri","year":"2008","unstructured":"Squitieri F, Cannella M, Frati L. Molecular medicine: predicting and preventing Huntington\u2019s disease. Neurol Sci 2008;29:205\u20137. doi: 10.1007\/s10072-008-0969-3 .","journal-title":"Neurol Sci"},{"key":"1103_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1755-5949.2008.00068.x","volume":"15","author":"F Squitieri","year":"2009","unstructured":"Squitieri F, Cannella M, Simonelli M, Sassone J, Martino T, Venditti E, et al. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size and age at onset prediction as early biomarkers of brain atrophy in Huntington\u2019s disease. CNS Neurosci Ther 2009;15:1\u201311.","journal-title":"CNS Neurosci Ther"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-009-1103-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-009-1103-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-009-1103-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T16:01:45Z","timestamp":1558713705000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-009-1103-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,11]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["1103"],"URL":"https:\/\/doi.org\/10.1007\/s00259-009-1103-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,11]]}}}